Central Centrifugal Cicatricial Alopecia Clinical Trial
Official title:
Barriers to Healthcare and Quality of Life for Central Centrifugal Cicatricial Alopecia Patients
The purpose of the current project is twofold; first to determine what personal, historical, logistical, and environmental factors preclude women from obtaining medical care for CCCA hair loss. Because damage from CCCA is irreversible, early identification and treatment is paramount to limiting the negative ramifications of the disease. Second, to investigate how CCCA hair loss, a common occurrence in the Black population, can be a significant psychological impediment to lives of affected Black women. Based on previous research on the psychosocial impact of generalized hair loss in Black women, it is fair to consider that CCCA hair loss also leads to problems with self-esteem and participation in daily life activities. This research, the first of its kind, will add to existing knowledge of CCCA by investigating the quality of life and barriers to care of patients with this condition. The goal of this study is to illuminate what stands in the way of secondary and tertiary prevention of CCCA patients and tailor treatment strategies to address their needs. The results of this study will be instrumental in modifying dermatology resident training, adding to existing dermatology management guidelines, and even developing public health advocacy programming.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03521687 -
Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA)
|
Phase 4 | |
Not yet recruiting |
NCT05416333 -
Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)
|
Early Phase 1 | |
Recruiting |
NCT04764331 -
A Pilot Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia
|
N/A | |
Recruiting |
NCT05759338 -
A Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia
|
N/A | |
Completed |
NCT03346668 -
Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia
|
Early Phase 1 | |
Withdrawn |
NCT05416320 -
Calcipotriol as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)
|
Early Phase 1 | |
Completed |
NCT04342091 -
Follicular Revival in Fibrosing Alopecia: Evaluating Use of Micro-needling
|
N/A |